Our perspectives
in one place
Topic
Selected filters
ClearNews
See allAMATA statement on the Framework for strengthening local production of medicines, vaccines, and other health technologies in the WHO African Region 2025-2035
On 29 August at the 74th WHO Africa Regional Committee Meeting in Brazzaville, Republic of Congo, the African Medicines Agency Treaty Alliance delivered a statement on Agenda item 10: Framework for strengthening local production of medicines, vaccines, and other health technologies in the WHO African Region 2025-2035.
Read moreIFPMA statement on the Framework for strengthening local production of medicines, vaccines, and other health techonologies in the WHO African Region 2025-2035
On 28 August at the 74th WHO Africa Regional Committee Meeting in Brazzaville, Republic of Congo, IFPMA submitted a statement on Agenda item 10: Framework for strengthening local production of medicines, vaccines, and other health technologies in the WHO African Region 2025-2035.
Read moreSecond meeting of the Ad Hoc Open-ended Working Group on Benefit-sharing from the Use of Digital Sequence Information (DSI)
On 12 August 2024, IFPMA delivered a statement at the second meeting of the Ad Hoc Open-ended Working Group on Benefit-sharing for the use of Digital Sequence Information (DSI) in Montreal, Canada.
Read moreTenth meeting of the Intergovernmental Negotiating Body (INB)
On 16 July 2024, IFPMA delivered a statement at the tenth meeting of the Intergovernmental Negotiating Body (INB) in Geneva, Switzerland.
Read morePharmaceutical industry welcomes the launch of Gavi’s new investment round and AVMA
On 20 June in Paris, Gavi, the Vaccine Alliance, the Government of France and the African Union – together with Team Europe partners, co-hosted The Global Forum for Vaccine Sovereignty and Innovation.
Read morePharmaceutical industry response to pandemic preparedness agreements at World Health Assembly
On 1 June, member states represented at the World Health Assembly agreed on amendments to the International Health Regulations (2005), alongside the decision to complete negotiations on a pandemic agreement within a year. The pharmaceutical industry shared its response.
Read morePublications
See allSustainable access to effective antibiotics
In a new position paper, IFPMA explores some of the challenges in ensuring access to safe and quality-assured antibiotics and propose a set of policy changes for consideration.
Read more
The Value of Reference Agency Assessment Reports in Enabling Regulatory Reliance
Access to information, including the assessment documents of reference national regulatory agencies (NRA), is a key enabler of regulatory risk-based decision making. It promotes an understanding of what was reviewed by the reference NRA, provides a rationale for decision making and promotes confidence and trust. The Centre for Innovation in Regulatory Science (CIRS) has published...
Read more
The development and manufacture of vaccines to protect global health (IFPMA & DCVMN)
IFPMA has partnered with DCVMN to share our industry’s expertise in vaccine development and manufacturing. This presentation illustrates the key stages and timeline to bring vaccines to the market.
Read more
Expert insights
See all
Adult immunization: Powerful new evidence for a prevention-first mindset
Read more
Now is the time for sustainable financing for NCDs and mental health
Read more
Operationalising the African regulatory ecosystem for the benefit of all patients
Read moreResources
See allOur Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more
February 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more
Action on NCDs: How the innovative pharmaceutical industry helps bridge the care gap
Read more